Remitting multiple sclerosis: Natalizumab reduces relapses and disability

www.eurekalert.org

Public release date: 4-Oct-2011
Contact: Jennifer Beal
Wiley-Blackwell
Remitting multiple sclerosis: Natalizumab reduces relapses and disability

Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic review published in the latest edition of The Cochrane Library.

Multiple sclerosis (MS) is a disease that damages a person's nervous system. The symptoms vary considerably from person to person, but many have a form of the disease in which they feel healthy for a time, and then relapse into periods of ill health. Over time, the disease tends to develop into a permanent disability. The aim of many treatments is to increase the period of remission that MS patients have between each relapse, and to delay the progression to the full disease for as long as possible.

[...]

..